Development of a New Sensor for - Paris, France - PHENIX

PHENIX

Entreprise vérifiée

Paris, France

il y a 3 semaines

Posté par:

Sophie Dupont

beBee Recruiter

Description

Development of a New Sensor for Metastasis-Initiating Cells Detection based on Molecularly Imprinted Polymers:

Réf
ABG-123890
Sujet de Thèse 15/05/2024
Contrat doctoral
PHENIX
Lieu de travail
Paris
IledeFrance
France
Intitulé du sujet
Development of a New Sensor for Metastasis-Initiating Cells Detection based on Molecularly Imprinted Polymers
Champs scientifiques
Chimie

Description du sujet:

Breast cancer is the most common cancer in women, affecting almost one in eight women worldwide, and the second cause of cancer deaths in women. Despite advances in diagnostic and treatment of breast cancer, 4% to 10% of women will present a metastatic disease at the time of diagnosis. Furthermore, up to 30% of patients with early stage tumors will develop distant metastases after primary treatment. Persistence of breast cancer stemlike cells (BCSCs) are considered as a major mechanism for breast cancer progression, metastasis and recurrence [1]. A key characteristic of BCSCs is their tumorforming ability and innate drug resistance mediated by their relative quiescence within the tumour core. These cells also involve molecular mechanisms enabling them to evade the cytotoxic effects of anti cancer drugs and to migrate to form metastasis [23]. In the recent years, a better definition of the phenotype of these cells has been proposed allowing their detection both in the primary tumor and the metastasis. However, their identification in the bloodstream (liquid biopsy) would be of great interest as biomarkers for diagnostic, patient monitoring and as potential therapeutic target to limit the apparition of metastasis, which is the main event, correlated with prognostic.
MIPbased sensors have been investigated as promising analytical devices in clinical analysis because they are cheap, portable, give a fast response and they are specific [4]. In cancer diagnosis, MIPbased sensors exploiting different detection techniques for cancer biomarker sensing have been developed for several years [5] using prostate specific antigens, alpha fetoprotein, carcinoembryonic antigens, cancer antigen 125, among others. However, none have considered the detection of CTCs.
We aim to develop an emerging promising method for CTC detection based on Molecularly Imprinted Polymers (MIPs). MIPs are synthetic materials that exhibit excellent binding properties with affinities and selectivities comparable to those of antibodies.
The project is in collaboration with Tokyo University.

Nature du financement:

Contrat doctoral

Précisions sur le financement:

Présentation établissement et labo d'accueil:

PHENIX

Les recherches au sein de PHENIX reposent sur une triple compétence : une expertise certaine et reconnue dans l'expérimentation et la synthèse chimique, la capacité de mettre en œuvre des simulations numériques sur un très large domaine d'échelles de longueur et de temps, et un effort certain dans le développement de modèles théoriques adaptés. 22/05/2024